Hemoglobin disorders: a look to the future.
In this issue of Blood, Locatelli et al compare the results of histocompatible family donor bone marrow and cord blood transplants (BMT and CBT) for severe β thalassemia (SBT) and sickle cell disease (SCD) as experienced by the Eurocord and European Blood and Marrow Transplantation group and collaborating centers in the United States, Hong Kong, and Israel between 1994 and 2005. Obviously, many changes in medical care and particularly MHC typing occurred over that decade, so this retrospective represents a moving target, but some firm points can be made for which we are indebted to this excellent group.
Dana-Farber Cancer Institute.
David G
DG
Nathan
D016026:Bone Marrow Transplantation / Q000379:methods*; D005260:Female; D005312:Fetal Blood / Q000637:transplantation*; D006680:HLA Antigens / Q000276:immunology*; D006453:Hemoglobinopathies / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D008297:Male
D006680:HLA Antigens